New antibiotic for hospital superbug looks promising

Oct 12, 2010
New antibiotic for hospital superbug looks promising
Image: Clostridium difficile. Credit: Annie Cavanagh/Wellcome Images

A new class of antibiotic specifically designed to target the hospital superbug Clostridium difficile has proved to be more effective than current treatments in preclinical studies.

According to results reported today by UK company Summit, the new compound clears C. difficile and provides total protection from recurrence in an animal model of infection. The compound is also effective against a panel of clinical isolates taken from people infected with C. difficile.

The new antibiotic is being developed with support from a Wellcome Trust Seeding Drug Discovery award.

The new findings show that SMT 19969 targets C. difficile with greater specificity than any other known antibiotic, while leaving the natural populations of in the gut unharmed. This is important because ‘friendly’ bacteria in the gut are needed to aid with digestion and are a natural part of the body’s defences against invading bacteria.

Antibiotic resistance is an increasing concern but the findings show an unprecedentedly low incidence of bacterial resistance to the new compound - significantly lower than for any other antibiotic targeting C. difficile.

William Weiss, Director of Pre-Clinical Services at the University of North Texas Health Science Centre in Fort Worth, who collaborated on the preclinical studies, explained: “These results are very promising and show that SMT 19969 exhibits a clearly defined antibiotic effect and is superior to currently approved treatment options. If these results are replicated in man, SMT 19969 has the potential to become a new and highly effective antibiotic for the treatment of C. difficile infections.”

Steven Lee, Chief Executive Officer at Summit, added: “The positive results reported demonstrate the tremendous progress that our C. difficile programme has made, and with the financial support of the Wellcome Trust, Summit looks forward to continuing to advance SMT 19969 through to human clinical trials.”

C. difficile is a life-threatening infection for which the only current therapy options are broad-spectrum - which are not very effective, meaning that recurrence rates are high. In 2009 in the UK, C. difficile was responsible for approximately five times more deaths than MRSA, while the combined annual cost of care in Europe and North America is estimated at $7 billion (£4.4bn).

Rick Davis, Business Development Manager at the Wellcome Trust, commented: “C. difficile infections pose a serious healthcare challenge and there is a pressing need to develop new antibiotic treatments. The Wellcome Trust is pleased with the excellent progress Summit has made towards development of a potential new treatment.”

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

C. difficile and antibiotics not necessarily linked

Oct 07, 2008

The latest study by Dr. Sandra Dial from the Research Institute of the MUHC, McGill University, and Attending Staff in the Intensive Care Unit at the Jewish General Hospital, questions the assumption held by a vast majority ...

The balance shifts

May 27, 2008

The risk of contracting a Clostridium difficile infection following operations for which a "prophylactic" antibiotic is given to prevent infection is 21 times greater now than it was just a decade ago, according to researchers ...

APIC launches first national C. difficile prevalence study

Mar 20, 2008

The Association for Professionals in Infection Control and Epidemiology (APIC) today announced a detailed strategy to combat Clostridium difficile-associated disease (CDAD). The initiative begins with the first national prevalence ...

Scientists go into battle to disarm superbug

Mar 19, 2010

(PhysOrg.com) -- Two recent pieces of research from Imperial College London reveal new ways of tackling the armour and weapons of Clostridium difficile, the ‘superbug’ that causes severe infections in ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0